You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Uterine Adenosarcoma
Contributor:
Ulrich, Uwe A.;
Denschlag, Dominik
Published:
S. Karger AG, 2018
Published in:
Oncology Research and Treatment, 41 (2018) 11, Seite 693-696
Language:
English
DOI:
10.1159/000494067
ISSN:
2296-5270;
2296-5262
Origination:
Footnote:
Description:
Uterine adenosarcoma is a rare malignancy. It is defined as a biphasic tumor composed of both sarcomatous stroma and benign epithelium. While the sarcomatous component usually is a low-grade homologous uterine sarcoma, the epithelium most often consists of endometrium-like cells. If the sarcomatous part occupies more than 25% of the tumor volume, the situation is referred to as sarcomatous overgrowth - accounting for about 10% of cases. While adenosarcoma usually may be considered a tumor of low malignant potential, the sarcomatous overgrowth most often presents as high-grade sarcoma and is associated with aggressive clinical behavior. Adenosarcomas stage I without sarcomatous overgrowth have a rather good prognosis, with a 5-year overall survival up to 80%. For treatment, complete surgical removal is advocated. Adjuvant chemotherapy and radiotherapy are not defined. Recurrences should again be treated surgically, attempting to achieve complete tumor resection. While the optimum medical treatment for relapsed and metastasized adenosarcomas has yet to be found, chemotherapy and endocrine therapy are potential options.